Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 517125100 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Blue Owl Capital Holdings LP 13G/A Amendment 3 | 10.0% |
5/14/2026
Event 3/31/2026
|
|
|
Millennium Management LLC
13G/A
Amendment 2
|
3.5% |
4/30/2026
Event 3/31/2026
|
|
| Millennium Management LLC | 3.5% | ||
| Millennium Group Management LLC | 3.5% | ||
| Israel A. Englander | 3.5% | ||
|
James E. Flynn
13D/A
Amendment 11
|
34.4% |
3/2/2026
Event 2/27/2026
|
|
| Deerfield Private Design Fund III, L.P. | 10.3% | ||
| Deerfield Healthcare Innovations Fund, L.P. | 7.9% | ||
| Deerfield Private Design Fund IV, L.P. | 10.3% | ||
| Deerfield Partners, L.P. | 6.0% | ||
| Deerfield Mgmt III, L.P. | 10.3% | ||
| Deerfield Mgmt HIF, L.P. | 7.9% | ||
| Deerfield Mgmt IV, L.P. | 10.3% | ||
| Deerfield Mgmt, L.P. | 6.0% | ||
| Deerfield Management Company, L.P. | 34.4% | ||
| James E. Flynn | 34.4% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 1
|
0% |
2/17/2026
Event 12/31/2025
|
|
| RA Capital Management, L.P. | 0% | ||
| Peter Kolchinsky | 0% | ||
| Rajeev Shah | 0% | ||
| RA Capital Healthcare Fund, L.P. | 0% | ||
| Blue Owl Capital Holdings LP 13G/A Amendment 2 | 10.0% |
2/12/2026
Event 12/31/2025
|
|
|
Millennium Management LLC
13G/A
Amendment 1
|
5.8% |
11/6/2025
Event 9/30/2025
|
|
| Millennium Management LLC | 5.8% | ||
| Millennium Group Management LLC | 5.8% | ||
| Israel A. Englander | 5.8% | ||
|
Opaleye Management Inc.
13G
|
4.8% |
8/29/2025
Event 8/29/2025
|
|
| Opaleye Management, Inc. | 4.8% | ||
| Opaleye, L.P. | 4.8% | ||
| James Silverman | 4.8% | ||
| Janus Henderson Group PLC 13G/A Amendment 5 | 0% |
8/14/2025
Event 3/31/2025
|
|
|
James E. Flynn
13D/A
Amendment 10
|
35.8% |
7/31/2025
Event 7/31/2025
|
|
| Deerfield Private Design Fund III, L.P. | 11.1% | ||
| Deerfield Healthcare Innovations Fund, L.P. | 8.6% | ||
| Deerfield Private Design Fund IV, L.P. | 11.1% | ||
| Deerfield Partners, L.P. | 4.9% | ||
| Deerfield Mgmt III, L.P. | 11.1% | ||
| Deerfield Mgmt HIF, L.P. | 8.6% | ||
| Deerfield Mgmt IV, L.P. | 11.1% | ||
| Deerfield Mgmt, L.P. | 4.9% | ||
| Deerfield Management Company, L.P. | 35.8% | ||
| James E. Flynn | 35.8% | ||
|
Millennium Management LLC
13G
|
5.6% |
6/17/2025
Event 6/12/2025
|
|
| Millennium Management LLC | 5.6% | ||
| Millennium Group Management LLC | 5.6% | ||
| Israel A. Englander | 5.6% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 4
|
8.7% |
5/14/2025
Event 3/31/2025
|
|
| Janus Henderson Group PLC | 8.7% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 9.1% | ||
|
Goldman Sachs Group Inc
13G/A
Amendment 1
|
4.1% |
5/13/2025
Event 3/31/2025
|
|
| The Goldman Sachs Group, Inc. | 4.1% | ||
| Goldman Sachs & Co. LLC | 4.1% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.8% |
4/22/2025
Event 3/31/2025
|
|
|
Opaleye Management Inc.
13G
|
6.2% |
4/16/2025
Event 4/9/2025
|
|
| Opaleye Management, Inc. | 6.2% | ||
| Opaleye, L.P. | 6.2% | ||
| James Silverman | 6.2% | ||
| BlackRock, Inc. 13G | 5.1% |
2/4/2025
Event 12/31/2024
|
|
|
Janus Henderson Group PLC
13G/A
Amendment 3
|
10.1% |
1/8/2025
Event 12/31/2024
|
|
| Janus Henderson Group PLC | 10.1% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 8.5% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 6.14 k | $19.6 k |
| 2026 Q2 | 171 | 95.5 M | $293 M |
| 2026 Q1 | 171 | 87.8 M | $395 M |
| 2025 Q4 | 140 | 72.7 M | $277 M |
| 2025 Q3 | 154 | 85.5 M | $275 M |
| 2025 Q2 | 127 | 62.4 M | $180 M |
| 2025 Q1 | 109 | 60.8 M | $132 M |
| 2024 Q4 | 125 | 63.4 M | $245 M |
| 2024 Q3 | 130 | 64.4 M | $421 M |
| 2024 Q2 | 116 | 65.4 M | $474 M |
| 2024 Q1 | 119 | 63.8 M | $484 M |
| 2023 Q4 | 78 | 39.7 M | $181 M |
| 2023 Q3 | 70 | 38.8 M | $153 M |
| 2023 Q2 | 68 | 39.0 M | $120 M |
| 2023 Q1 | 71 | 38.5 M | $174 M |
| 2022 Q4 | 51 | 38.8 M | $160 M |
| 2022 Q3 | 63 | 40.9 M | $131 M |
| 2022 Q2 | 42 | 14.4 M | $28.2 M |
| 2022 Q1 | 49 | 15.3 M | $61.8 M |
| 2021 Q4 | 51 | 14.7 M | $158 M |
| 2021 Q3 | 56 | 14.5 M | $167 M |
| 2021 Q2 | 47 | 14.5 M | $143 M |
| 2021 Q1 | 58 | 14.1 M | $206 M |
| 2020 Q4 | 44 | 14.3 M | $305 M |
| 2020 Q3 | 39 | 13.6 M | $207 M |
| 2020 Q2 | 38 | 13.0 M | $166 M |